The Pepper Bough

GE sells Biopharma for 21 billion dollars

Cole Marullo, Reporter

Hang on for a minute...we're trying to find some more stories you might like.


Email This Story






General Electric Co. sells Biopharma to Danaher Corp. for $21.4 billion, its first major asset sale under new Chief Executive Officer, Larry Culp. The announced sale was a short-term windfall for the company. Its shares increased nearly 17 percent Monday but it may also be a long-term investment, according to industry observers in Connecticut, where bioscience industries have thrived in recent years.

This deal will help General Electric help pay off their $100 billion dollar debt that they have acquired over multiple years.

The BioPharma unit makes software that supports the research and development of pharmaceuticals. It brought in $3 billion in revenue last year.

Last year HE rejected an approach by Danaher for that business a year ago. But that mindset changed after Culp was appointed CEO and GE boards became more open to a deal.

As a result, GE will receive some $20 billion in net proceeds which it will use to trim its debt pile which is at a total of $121 billion at the end of December.

“Today’s transaction is a pivotal milestone,” Culp said in a statement.

“It demonstrates that we are executing on our strategy by taking thoughtful and deliberate action to reduce leverage and strengthen our balance sheet,” Culp said in a statement.

“It takes time” for pharmacy-based products seven to 15 years, Wurzer said. Culp was hired to turn around GE last fall, becoming the conglomerates first ever outsider CEO Culp secured a handsome pay that would give him more than $310 million in total compensation if he can lift GE shares to about $31 by the end of September 2022. Larry Culp “has earned his job before him, John Flannery or Jeff Immelt would have probably been able to pull off this transaction with Danaher,” William Blair and Co analyst, Nicholas Heymann, said.

After this sale, both companies shares skyrocketed. Danaher, the company that bought biopharma for $21 billion dollars, shares spiked, General Electrics shares spiked 34.4% over the past three months and Danaher shares climbed 10.8% according to The Street.

 

 

Print Friendly, PDF & Email
Navigate Left
  • GE sells Biopharma for 21 billion dollars

    Top Stories

    The most anticipated movie of the year is only one week away

  • News

    LA pays respect to legend Nipsey Hussle

  • GE sells Biopharma for 21 billion dollars

    Arts and Entertainment

    Colton High School’s Shrek the Musical is a success

  • GE sells Biopharma for 21 billion dollars

    Opinion

    Here’s the difference between high school and college

  • GE sells Biopharma for 21 billion dollars

    Top Stories

    Ribbon cutting ceremony for stadium brings Colton community together

  • GE sells Biopharma for 21 billion dollars

    Top Stories

    Day 28 of the Government Shutdown: How is America holding up?

  • GE sells Biopharma for 21 billion dollars

    Opinion

    What type of tree should your family get for Christmas?

  • GE sells Biopharma for 21 billion dollars

    Opinion

    Homework given during breaks causes stress during the holiday season

  • GE sells Biopharma for 21 billion dollars

    Top Stories

    Marvel Universe creator Stan Lee passes at 95

  • GE sells Biopharma for 21 billion dollars

    Sports

    MMA is not getting the recognition it deserves

Navigate Right
Keeping Colton High School informed and entertained since 1917
GE sells Biopharma for 21 billion dollars